.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,072,836

« Back to Dashboard
Patent 9,072,836 protects ADLYXIN and is included in one NDA.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 9,072,836

Title:Drive mechanism for a drug delivery device and drug delivery device
Abstract: A lead screw, a lead screw nut and a drive member are aligned with an axis defining an axial direction and an opposite axial direction. A coupling between the lead screw and the lead screw nut allows a helical movement of the lead screw with respect to the lead screw nut at least in the axial direction. The lead screw is coupled with the drive member, the coupling generating a helical movement of the lead screw with respect to the drive member when the drive member is moved in the axial direction with respect to the lead screw. A dispense stop feature of the lead screw nut and a dispense stop feature of the drive member prevent the generation of the helical movement of the lead screw when a specified end position of the drive member is approached.
Inventor(s): Plumptre; David Aubrey (Worcestershire, GB)
Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:13/825,841
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 5th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYes9,072,836► subscribeY
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYes9,072,836► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,072,836

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10186736Oct 6, 2010
PCT Information
PCT FiledOctober 05, 2011PCT Application Number:PCT/EP2011/067418
PCT Publication Date:April 12, 2012PCT Publication Number: WO2012/045794

International Patent Family for Patent: 9,072,836

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina083300► subscribe
Australia2011311617► subscribe
Brazil112013006949► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc